CEL-SCI Corporation (CVM, Financial) has finalized the preparation of its application for Breakthrough Medicine Designation for its treatment, Multikine, targeting head and neck cancer. This immunotherapy is administered prior to surgery for patients who have been newly diagnosed and previously untreated. The application is set to be submitted to the Saudi Food and Drug Authority (SFDA) through a prominent Saudi pharmaceutical and healthcare partner of the company.
The formal submission to the SFDA is anticipated to occur within the next few weeks. Once submitted, the SFDA typically takes around 60 days to respond to such applications. The development marks a significant step for CEL-SCI in expanding the reach of Multikine in international markets.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for CEL-SCI Corp (CVM, Financial) is $222.00 with a high estimate of $300.00 and a low estimate of $180.00. The average target implies an upside of 4,244.42% from the current price of $5.11. More detailed estimate data can be found on the CEL-SCI Corp (CVM) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, CEL-SCI Corp's (CVM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
